Edwards, C. et al. Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody11-1F4 (CAEL-101) in Patients with AL Amyloidosis.  16th International Symposium on Amyloidosis (ISA); 2018.

Edwards, C. et al. Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody 11-1F4 (CAEL-101) in Patients with AL Amyloidosis. 59th Annual American Society of Hematology; 2017. Abstract 509.

Edwards, C. et al. Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. 58th Annual American Society of Hematology; December 2016. Abstract 643.

Hrncic R, Wall JS, et al. Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits. Am J Pathol 2000; 157(4): 1239-1246.

Langer, A, et al. Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. 57th Annual American Society of Hematology; December 2015. Abstract 188.

O’Nuallain B, et al. Phage Display and Peptide Mapping of an Immunoglobulin Light Chain Fibril-Related Conformational Epitope. Biochemistry 2007; 46(45): 1349-58.

O’Nuallain B, et al. Localization of a Conformational Epitope Common to Non-Native and Fibrillar Immunoglobulin Light Chains. Biochemistry 2007; 46(5): 1240-1247.

Solomon A, Weiss DT, Wall, JS. Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid Reactive Monoclonal Antibodies. Cancer Biother Radiopharm 2003; 18(6): 853-60.

Wall JS, Kennel SJ, et al. Radioimaging of Light Chain Amyloid with a Fibril Reactive Monoclonal Antibody. J Nucl Med 2006; 47(12): 2016-2024.

Wall JS, Solomon A, Kennel SJ. Development and Evaluation of Agents for Targeting Visceral Amyloid. Tijdschr Nucl Geneeskd 2011; 33(4): 807-814.

Wall JS, et al. Radioimmunodetection of Amyloid Deposits in Patients with AL Amyloidosis. Blood 2010; 116(13): 2241-4.